Albert Bourla

Stories

First Lyme disease vaccine in two decades edges toward approval after Phase 3 trial

As of August 2026: Leading Pfizer's regulatory submission strategy for the Lyme vaccine

The vaccine, now formally designated PF-07307405 (also called LB6V, and previously known as VLA15), cleared its first regulatory hurdle since March's Phase 3 results. On August 14, 2026, the European Medicines Agency validated Pfizer and Valneva's marketing application, meaning the dossier is complete and formal review can begin.

Updated Aug 15